Delcath Systems, Inc. (DCTH)
Chart Events
Performance Outlook
| Previous Close | 2.8500 |
| Open | 2.8500 |
| Bid | 2.8400 x 1100 |
| Ask | 2.8600 x 900 |
| Day's Range | 2.8101 - 2.9200 |
| 52 Week Range | 2.2500 - 7.9900 |
| Volume | |
| Avg. Volume | 335,352 |
| Market Cap | 62.831M |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.4400 |
| Earnings Date | Nov 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DCTH
Related Research
- Delcath Systems, Inc.MMSI: Lowering target price to $56.00MERIT MEDICAL SYSTEMS INC has an Investment Rating of SELL; a target price of $56.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.RatingFair ValueEconomic Moat8 days agoArgus Research
PR NewswireDelcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal Melanoma Research. The publication, entitled "Quality of Life After Melphalan Hepatic Perfusion for Uveal Melanoma", was based on an independent clinical study conducted by investigators from University Hospital Southampton, UK and focused on the impact of melphalan percutaneous hepatic
- PR Newswire
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of five individuals.
- PR Newswire
Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update
Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2023.
